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Clinical trial research is performed across the world and is an important component of 
research administration. The complexity of clinical trials highlights the importance of the initial 
stages of clinical trial set up within an institution. Without a proper process, lengthy agreement 
and contract negotiations get drawn out even further, and poor document management leads to 
extensive delays in getting appropriate information to the institution, sponsor, and research 
group. While policies and procedures are available within Johns Hopkins, the way in which 
clinical trials are managed within the Department of Medicine is reliant upon individuals 
working on trials in their respective divisions. This means, analysts and researchers must rely on 
word of mouth, and co-workers as to who they contact to get their clinical trial up and running. 
This researcher surveyed anonymous individuals within the research administration field to 
assess if the clinical support issues run into by the researcher was a common issue amongst 
others in the field of clinical trial management.  While the number of participants was much less 
than expected, the results echoed the researcher’s hypothesis, in that the need for internal clinical 
trial management guides is dire. In question 5 of the survey, participants were asked “Does your 
institution provide clear policy and management structure guidelines regarding clinical trial 
management?”; 90% of participants answered no (Best, 2020). 
The results from the survey, literature review, and personal experience of the researcher, 
were then utilized to develop the Department of Medicine Initial Clinical Trial Management 
Guide within Appendix A. While there are many steps within the clinical trial management 
process, the researcher focused on the first step in getting a clinical trial initiated within an 
institution. The guide provides users with definitions, essential departmental contact information, 
checklists, forms, and email templates, to guide them through the initial steps of a clinical trial 






initiated within the Johns Hopkins University Department of Medicine. Although much support 
is still needed to assist analysts in managing clinical trials, this guide fills a hole within the Johns 
Hopkins University Department of Medicine in the initial stages of clinical trial management. 
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Clinical trial management is a time consuming and critical activity in sponsored research. 
The pre to post award process of a clinical trial can take several months with a number of 
intricate details that must be negotiated, and agreed upon long before a clinical trial can begin. In 
addition to the difficulty in managing a clinical trial, the support and institutional management 
systems vary greatly causing additional issues and problems for all parties involved with a 
clinical trial. While many institutions have designated Clinical Trial Offices, many institutions 
do not, or have a variation of a Clinical Trial Office.  The organizational structure in which a 
Clinical Trial Office is a centralized part of research institutions is one even the largest research 
institutions like Johns Hopkins have not solidified. This structural gap can and does have 
detrimental consequences to the retention and management of sponsored funds which could 
jeopardize current and potential funding opportunities.  
Researchers within the Johns Hopkins University and Johns Hopkins Health systems are 
very much on their own in terms of clinical trial support regarding the management of clinical 
trials. Offices such as the Office of Research Administration, Sponsored Projects Shared 
Services, and Clinical Research Support Services, exist and are crucial to the support of clinical 
trial work flow and clinical trial management. Those offices, which are key to work flowing 
clinical trials through the appropriate JHU channels, are very much isolated in their own 
departments and work interpedently of departmental offices where the clinical trial research is 
performed. This meaning that researchers and clinical trial personnel must understand the 
intricate workings of those offices, and what those offices can provide in terms of research 
administration to their specific clinical trial or sponsored project support.  






This thesis looks at the Clinical Trial Office structure that exist within some research 
institutions, identifies the common issues research administrators face regarding clinical trial 
management, and provides clinical trial management best practices that can be utilized  by 
researchers or clinical trial personnel to better assist them in managing the initial stages of their 
clinical trial within their respective institutions.  Based on this information, an initial clinical trial 
management guide for research administrators was developed.  
Review of the Literature 
 
The topic of clinical trial management has been discussed in the research community for 
many years. While topics such as types and sizes of trials has been discussed by the Farrell et. al 
article Managing Clinical Trials, specifics regarding how those trials should and could be 
managed has not been prevalent in those publications (Farrell, 2010). In the article titled 
“Managing Clinical Trials” by Farrell, et. al., the authors mention that ‘randomized trials 
involves a huge investment of time, money and people; therefore, it warrants expert management 
and needs to be managed from its inception like any other business. Due to the extensive 
demands and finite details that are structured into trials, the lack of clinical trial management 
structure can and has caused trials to fail or research not to be explored to its full capacity. As 
Farrell et. al, points out, “clinical trial management is essential amongst the key competencies 
that are needed to deliver high-quality trials”.  
To ensure clinical trials are managed optimally, research institutions should incorporate 
systematic structures of support for clinical trial management.  In a study done by the 
Association of Academic Health Centers, it was found that Clinical Trial Offices or CTOs have 
in recent years been incorporated into the academic health center research infrastructure as a way 
to consolidate administrative activities related to clinical trials, specifically from protocol 






development to billing compliance (Rubin, Lazar, 2018). In 2008, the Association of Academic 
Health Centers chose to look at eight universities which incorporated a CTO in order to learn 
about the scope and operations of those offices within those institutions (Rubin, Lazar, 2018).  
As Rubin and Lazar point out in their article, each of the institutions that were chosen to review 
had varying approaches to the management of clinical trial research. While not leading readers 
regarding which CTO was the “correct” choice to be implemented across research institutions, 
the need for a CTO, and the structure a CTO provides in regards to managing clinical trial and 
sponsored projects was apparent in each of the eight institutions whose CTO were analyzed.  
When formal CTOs are not established in research institutions, personnel new to managing 
clinical trials must learn to navigate institutional policies involving clinical trials on their own. 
When support, which comes from an established CTO, is missing, communication between 
departments and institutional compliance offices is hindered, understanding regarding 
institutional compliance policies in respect to trials is missed, thus resulting in the failure to 
manage clinical trials in a timely and compliant way. If no CTOs are in place on an institutional 
level, small departments within those research institutions suffer significantly. The article by 
Rubin and Lazar (2018) points out, the current administrative landscape within research 
institutions is complex.  
Many interdependent functions are spread across the research enterprise, which often 
results in the establishment of administrative structures and small bureaucracies operating 
as separate, unconnected silos that lack policies or formal procedures for communications 
and interaction (Rubin, Lazar, 2018).   
With institutions operating as individual entities within the institution as a whole, with no 
support or structure from a formal CTO office, smaller departments must create their own 






policies to follow in managing clinical trials. In terms of clinical trial management, a couple 
smaller departments provide their clinical trial personnel with access to department created 
clinical trial management guides. The University of California, Davis Health (UC Davis Health) 
clinical trials office site offers their clinical trial personnel a Tools for Study Management 
website acting as a guide to assist new personnel in how clinical trial management. The site 
offers blank word and PDF templates personnel can copy and alter to meet their specific trial 
needs (UC Davis Health, 2020). The following categories offer blank documents to personnel to 
utilize and assist in their trial management: Protocol, Patient Management, Study Management 
Tools, Recruitment Tools (courtesy of Beth Harper, Clinical Performance Partners), Radiology 
Procedure Request Form, Pathology (Laboratory) Forms, Consent, Epic Certification for Part 11 
Compliance, Disclosure Tracking Database, IT Evaluation Forms, UC Davis W-9, IDS Fee Form 
(2015) (UC Davis Health, 2020).  
While the aforementioned categories provide a wealth of information, the Tools for Study 
Management site as a whole does not address which departments to contact specifically to 
submit trial data to initiate a trial, and how that data is tracked and reported in the UC Davis 
system. While boiler plate forms are necessary and extremely helpful, the procedural structure of 
how a trial is managed is missing from the UC Davis Health guide. In addition to UC Davis 
Health, the University of Pennsylvania Perelman School of Medicine Office of Clinical Research 
(OCR) Industry Sponsored Study Guide also provides personnel with a clinical trial management 
guide. Unlike UC Davis Health, the Perelman School of Medicine OCR Sponsored Study Guide 
provides personnel with a quick reference guide to 7 functional steps to “help Investigators and 
their team navigate clinical research from start-to-finish” (University of Pennsylvania Perelman 






School of Medicine, 2020). Personnel can quickly access the hyperlinked text which when 
clicked takes users to the section of the guide they click on as shown in figure 1 below.  
Figure 1 
1. Protocol Selection 
→ Study Start-up Phase 
2. Study and Site Feasibility Assessment 
3. Regulatory Submission and Approval   
4. Legal and Financial Review and Approval 
5. Site Activation 
6. Study Execution → Active Enrollment Phase 
7. Study Closure     → Close Out Phase 
When accessed, the hyperlinks provide personnel with a blanket guide that breaks each 
listed section into 3 columns titled Activity, Comments, and Resources. Within those sections, 
users get a brief explanation of prospective instances that crop up in clinical trial management 
(Activity), comments on how to address those instances (Comments), and finally a hyperlink to 
access for more information (Resources).  While the table and the guide are extremely useful in 
providing personnel with a blanket overview of what personnel can encounter when in a clinical 
trial, the guide itself does not provide direct contact information for users within the institution. 
While the site is password protected on most of the Resource links, if a person new to institution 
needing direct contact information for their department must navigate the general guide in hopes 
of finding their direct resource contact. Both guides researched are helpful in respect to the 
associated institution but lack structure and direct information to assist personnel in accessing 
useful and applicable resources in managing clinical trials. In researching external institutional 
guides, a new guide has been established tailored to the Johns Hopkins University Department of 
Medicine. This thesis acknowledges the short comings within the Johns Hopkins University 
Department of Medicine. To remedy those shortcomings, a clinical trial management guide for 






personnel in DOM departments has been created and provides an easy access breakdown of the 
structures within the JHU DOM in the clinical trial management world.    
Problem Statement 
 
The administrative process for clinical trial management is a complex and varying 
process for departments even within the same institution. Johns Hopkins University, Department 
of Medicine, is an example of situations where a number of issues in regards to the procedures 
surrounding the policies of clinical trial management. In a search of the phrase clinical trial 
management JHU, one will not be able to find a website link that can guide users through the 
clinical trial management process. There is no site and policy guide on clinical trial management 
does not exist. While institutions such as UC Davis Health and the University of Pennsylvania 
Perelman School of Medicine Office exist and consolidate all aspects of clinical trial 
management into a one stop guide for their personnel, many research institutions do not provide 
these necessary road maps. This thesis unlike UC Davis Health and the University of 
Pennsylvania Perelman School of Medicine Office provides an encompassing guide to provide 
specific direction and help for anyone within the Johns Hopkins Department of Medicine.  
Methodology 
 
This researcher has established a guide in which clinical trial management is done on a 
small departmental level basis specific to small divisions such as the Division of Allergy and 
Clinical Immunology which falls under the umbrella of the Johns Hopkins University 
Department of Medicine. After reviewing models of clinical trial management based on other 
institutional site guides, personal experience in managing clinical trials, and an extensive survey 
that illustrates the need for directional information on clinical trial management, this researcher 
has developed an initial stages clinical trial guide to be used by analysts within the JHU DOM 






that are new to managing clinical trials. The early stages of the guide development started with 
the researcher reflecting on her personal experiences in clinical trial management. Upon 
reviewing initial stages of a clinical trial, the researcher developed questions for a survey to 
researchers in the research administration field to identify the issues researchers most commonly 
come across in managing clinical trials. While the researcher could list the common problems 
faced when managing a trial, the survey would measure if others faced the same issues. The 
answers then generated a direction for the guide to take and addresses common issues faced by 
researchers in the clinical trial management field. In addition to results of the survey, the 
researcher based several structural elements of the guide on the University of Pennsylvania 
Perelman School of Medicine OCR Sponsored Study Guide. In incorporating the elemental 
structure from the Perelman School of Medicine OCR guide, the information throughout the 
guide is from the researcher’s findings on how to manage a clinical trial while following JHU 
policies and protocols. The researcher leaned on their knowledge of how to find the Johns 
Hopkins departmental sites, collected the information accessed, and placed the applicable 
information into the guide. a number of Johns Hopkins department links and In drawing from 
personal findings, researched guide structures from external institutions, and the answers from 
the IRB approved research administrator survey developed, to develop the guide as shown in 
Appendix A.   
Project Results 
 
As the surveying of Johns Hopkins personnel is limited and requires extensive IRB 
review and approval, this researcher crafted a clinical trial management survey specifically 
recruiting research administrators who are members of the group the National Council of 
University Research Administration also known as NCURA.  The researcher utilized NCURA 






message boards to advertise the survey and provided prospective participants with access to the 
link. The survey was posted on five separate messaging boards on the NCURA website, and was 
posted twice on the researchers’ personal LinkedIn page and was active for more than two 
months before being closed by the researcher. While the survey was available and accessible, the 
results only yielded 10 participants. The anticipation from the researcher was that 100 people 
would take the survey and those answers could either solidify or not the researchers’ thoughts. 
The researcher aimed to collect quantifying data that could address the hypothesis that clinical 
trial support and management is something missing in large research institutions across the 
United States. In only receiving a tenth of the expected responses to the survey, the researcher 
believes that a number of factors contribute to the low result turn out. The stemming factor being 
the COVID-19 outbreak. The COVID-19 pandemic outbreak initialized a national emergency 
and a shutdown of the United States in March of 2020 (Schuchat, 2020).  The initial shutdown 
rapidly forced the adjustment of everyday life to incorporate a primarily online based existence 
for research administrators. All exchanges between researchers and labs were virtualized, and 
institutions were forced online. Now virtual meetings, emails, and phones calls replaced the 
everyday in person exchanges adjusting communication flows constantly. While the researcher 
does not have direct evidence that the pandemic is the sole reason for the low participant 
participation, it is an easy correlation to make.  
The following questions were drafted to assess the clinical trial management deficiencies 
experienced by research administrators in this field, and confirms the overall hypothesis of this 
researcher in that the need for a clinical trial management guide is necessary for all research 
institutions. Comprised of 18 questions, the survey asked qualifying and consenting participants 
about their involvement with clinical trials within their institution. As this was an anonymous 






survey, information regarding the respective institutions that the participants work at was not 
collected to ensure the privacy and anonymity of the participants was maintained. The survey 
asked participants varying questions regarding their involvement with clinical trials. With 
NCURA being such a large organization with 7,500 members from over 1,100 colleges, one 
would assume that the results would vary greatly and in some instances they did (NCURA, 
2020). The participant total came to 10 people with varying job titles and experience in the 
clinical trial management process within their respective institutions. After reading about the 
purpose of the study, participants were asked to consent to take the survey. 
Figure 2 
 
Once consented, participants begin the survey in answering question one which asked what 
specific role they had within their institution. The job titles of the participants included 
administrators, research nurses, directors, directors of sponsored projects, and grants and 
contracts analysts (Best, 2020). This question aimed to highlight the varying roles of personnel 












Question 2 then narrowed down the participant pool to whether or not individuals were involved 
with clinical trials. If they answered no, participants were then not encouraged to continue the 
survey further.  
Figure 4 
 
In Question 3, the survey shifted the direction of the questions to analyze how many participants 
were involved with clinical trials from start to finish. Results yielded at 60% yes and 40% no 
(Best, 2020). 








Questions 4 narrows the survey further down to look at the clinical trial management training 
received by participants. As the survey results show, the variation in training is apparent. While 
50% of participants answered variations of institutional training, training by colleagues, word of 
mouth, self and being self-taught, 20% of participants answered they taught themselves, and 30% 
stated in person instruction or seminar courses (Best, 2020).  
Figure 6 
 
  Question 5 of the survey goes on to highlight an interesting deficiency within the research 
administration field. That while in question 4 personnel did receive some variation of training, in 






question 5, 90% participants answered that their institutions do not provide personnel with the 
tools, guides, and clear institutional policy and procedures they need to assist them in managing 




Breaking from the numbered sequence the next question categorized as a Management process 
Question type asked of participants, asks a pre-award focused section of questions attempting to 
highlight how involved personnel are in the beginning stages of a clinical trial.  
 








Upon answering the Management process Question, participants were then provided the 
following prompt: 
Figure 9 
Question 6 then asked participants specifically to answer what areas of pre-award they are 
responsible for. Of the 10 participants, 60% said they are responsible for correspondence and 
agreement negotiations, 80% said they’re responsible for budget development, 70% budget 
negotiations, 50% agreement development and agreement management, 30% Protocol 
Management (Institutional System), MTA, CTA, DUA, Management (Institutional System), 
20% MTA, CTA, DUA, Development, and 10% said they were responsible for data entry of 
sponsored systems (Best, 2020).  








Question 7 then asked participants to answer what departments they work with when setting up a 
clinical trial. The results, like question 6, yielded 8 participant responses and showed that 70% of 
participants answered they work with their institutional clinical research office and the industry 
contracts office, 60% of participants worked with their grants management office, 50% their 
compliance office, 40% sponsored projects shared services and office of research administration, 
30% technology transfer office, and 10% answered they worked with all the above offices (Best, 
2020) 1 person was null from this question and answered as such. 








In addition to gauging how many offices participants worked with in the initial stages of a 
clinical trial, question 8 of the survey aimed to measure the total number of persons participants 
interact with in the initial clinical trial stages. Question 8 results showed 50% of participants 
worked with 4-7 people, 10% said 8 or more people, 10% 1-3 people, and one person was listed 










Question 9 of the survey asked participants if they ran into a number of specific issues during the 
pre-award stages of clinical trials. Of the issues, 40% of participants said they run into lack of 
response, 30% answered all of the above issues listed including interpersonal communication 
issues, lack of response, lack of resources, and no definitive procedures, 10% said interpersonal 
communication issues, 10% no definitive procedures, and 10% said this question was not 
applicable to them (Best, 2020). 
Figure 13 
 
The researcher was then curious to see if those issues were resolved and asked participants in 
question 10 whether they were able to overcome those issues. Results showed 90% of 



















Delving further, the researcher specifically asked a fill in the blank question asking if the 
participant answered yes to question 10, please provide how they overcame those issues. Of the 
10 participants, 9 answered ranging in answers as shown in the screen shot below (Best, 2020). 
Figure 15
 






In question 11, the researcher asked participants to provide a short answer as to what 
organization techniques they would provide for new personnel managing the pre-award side of 




Question 12 wrapped up the pre-award survey questions and asked participants what they would 
tell new analysts working in clinical trials for the first time what not to do in terms of pre-award 
clinical trial management. While the individual answers are provided in the screen shot below, 
the theme of the answers revolved around the importance of communication. 









While the first half of the survey primarily focuses on the pre-award side to clinical trial 
management, most analysts who took the survey also stated that they work clinical trials from 
start to finish which include the pre to post award cycle of trial management. The post award 
questions specifically seek out answers to how individuals manage their post award side of 
clinical trials. Participants were then asked to answer another Management Process Question. Of 






the 10 participants, 80% stated no and 20% stated yes to specializing in post-award management 
of clinical trials (Best, 2020).  
Figure 18 
 
Question 13 asks participants which areas of post award are their responsibility which include 
duties such as billing and invoicing, tracking patient visits, clinical trial milestones, managing 
expenditures ensuring they’re allowable, allocable, and reasonable, report reconciliations, effort 
allocations and certification, award close out. While several participants acknowledged the post 
award side of clinical trial management was non-applicable, a number of participants noted that 
they were responsible for some or all of the aforementioned duties (Best, 2020). 4 participants 
said they’re responsible for billing and invoicing, 3 said they’re responsible for tracking patient 
visits, clinical trial milestones, report reconciliations, and all of the options listed above, 2 said 
managing expenditures ensuring they’re allowable, allocable, and reasonable, effort allocations 












Where question 13 asks participants what duties they’re responsible for, question 14 highlights 
the frequency analysts must be in contact with PI’s regarding clinical trials. While 3 people 
mentioned the question was not applicable to them, all other participants answered the question 













In question 15 the researcher aimed to discover what kind of systems the participants utilized 
when managing clinical trials. 40% answered personally developed word documents, excel 
sheets, etc., 20% answered they used institutional web-based tracking systems, and the other 
40% answered that this question was not applicable to them (Best, 2020). 
Figure 22 
 
Question 16 asked participants to answer what resources are available to them when they have 
concerns or questions regarding post award management of clinical trials. Of the 10 participants, 
only 9 chose to provide an answer. 22.2% answered all of the above from answer selections 






including mentor in current role, a designated manager or administrator who specializes in 
clinical trials/ sponsored research, and Institutional website with web-based policy guides. 11.1% 
answered a designated manager or administrator who specializes in clinical trials/ sponsored 
research, and the remaining participants answered this question was not applicable to them (Best, 
2020).  
Figure 23 
Question 17 then asked participants to provide a short answer to what organizational techniques 
they would pass along to an analyst working on the post-award side of clinical trial management. 
50% of participants provided specific techniques ranging from the importance of communication 
and organization, while the other 50% answered this question was not applicable to them (Best, 
2020).  








The final question of the survey question 18, then asked participants what advice they had to 
give new analysts on what not to do when managing the post-award side of a clinical trial for the 
first time. 50% answered variations of the importance of time management and organization, and 
50% answered the question did not apply to them (Best, 2020). 










While the survey results yielded only a small response rate, it is apparent that the clinical 
trial management deficiencies in the research administration field are wide spread amongst 
research institutions. To utilize the data and apply it to the initial clinical trial guide in Appendix 
A, the researcher noticed a few things in the results that lead to the guide development. Upon 
review of the survey results, the researcher found that the pre-award questions provided more 
detailed responses from participants. Per the first management process question, 90% of 
participants answered they specialized in the pre-award stages of clinical trials (Best, 2020). The 
researcher also noticed that the survey findings had more pre-award data from questions 6 and 13 
of the survey. In question 6, 90% of participants answered some variation of the pre-award duties 
listed (Best, 2020). When compared to the same question asked regarding post-award duties in 






question 13, only 50% of participants answered the duties were relevant to them (Best, 2020). 
With the vast majority of participants saying they specialized in pre-award, the researcher 
decided to focus on creating a pre-award initial clinical trial guide. Due to the pre-award 
responses, and from question 5 showing that 90% of participants said they had no clear clinical 
trial management structure, the researcher decided to tailor their guide to breakdown the JHU 
DOM pre-award clinical trial process in the form of the Appendix A guide (Best, 2020).  
The lack of managerial support, total self-guidance and reliance, and minimal access to 
training or institutional support guides are a few of the pressing and detrimental issues that 
analysts are facing in regards to clinical trial management. The research collected, and the 
literature reviewed, demonstrates the ever-present need for institutional support and training, as 
well as institutional based guides to assist all analysts working in the clinical trial management 
field. The researcher’s guide in Appendix A is a positive step forward in providing initial support 
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Clinical Trial Management Survey 
Thesis Survey Questionnaire 
Introduction  
 
Clinical trial research is performed across the world and is an important cornerstone within the 
field of research administration. The management work done by research administrators is 
crucial to the successes of clinical trials, because that work often determines whether funding is 
obtained, lost, or kept, based on how the trial is managed within a given institution. Nevertheless, 
the protocols for how clinical trial management is done varies greatly from one research 
institution to the next, which can hamper the effectiveness of the work we do.  
 
In an attempt to remedy these issues, Katherine Best, a graduate student in the Research 
Administration program at Johns Hopkins University, is researching these variations to clinical 
trial management styles at research institutions across the United States. She hopes to isolate 
common clinical trial management issues and use those findings to develop a universal clinical 
trial management guide that will help to streamline administration processes, thereby increasing 
departments' efficiency and making the complexities of this work easier to understand for 
newcomers to the field.   
 
You have been selected to take part in this survey because of your role in the research 
administration field. Your responses are important to the success of this research project even if 
you do not typically work on clinical trials. 
 
In completing this survey, you are consenting to be in this research study. Your participation is 
voluntary, and you can drop out at any time. All information will be stored in a password-
protected format. To protect your confidentiality, the survey does not contain information that 
will personally identify you. The results of this study will be used for scholarly purposes only 
and may be shared with Johns Hopkins University personnel.  
 























By selecting the agree button, you are confirming that you: 
 
1. are 18 years or older 
2. are a professional in the research administration field  
3. have read the information above 
4. agree to voluntarily participate in this study 
 
a. Agree 
b. Disagree  
 
General Questions 
1. What is your specific role at your institution? 
a. PI 
b. Research Nurse 
c. Administrative Coordinator 
d. Administrator  
e. Grants and Contracts Analyst 
f. Other___ 
2. Are you involved with any aspect of clinical trials within your institution? 
a. Yes 
b. No 
3. Do you manage the clinical trial from start to finish? 
a. Yes 
b. No 
4. How were you trained to manage clinical trials? 
a. Online recorded lecture 
b. In person instructor or seminar course 
c. Word of mouth  
d. Self-taught 
e. Other___ 
5. Does your institution provide clear policy and management structure guidelines regarding 




Management Process Questions 




If you answered "Yes" to the above question, please answer questions 7-13. If you answered 
"No," proceed to question 14. 
 
6. Please select the pre-award responsibilities that align with your role in terms of clinical 
trial management from the list below. Check all that apply. 
a. Correspondence  






b. Data Entry, institutional systems 
c. Data Entry, sponsor systems 
d. Budget development  
e. Budget negotiations 
f. Protocol Development 
g. Protocol Management (Institutional System) 
h. MTA, CTA, DUA, Development 
i. MTA, CTA, DUA, Management (Institutional System) 
j. Agreement Development 
k. Agreement Negotiations 
l. Agreement Management 
m. All of the above 
n. Other______ 
      7   Select all of the departments you work with in setting up a clinical trial 
a. Grants Management Office 
b. Sponsored Projects Shared Services 
c. Clinical Research Office 
d. Office of Research Administration 
e. Industry Contracts Office 
f. Technology Transfer Office 
g. Compliance Office 
h. All of the above 
i. Other____ 
8 How many people are you in contact with during the beginning stages of a clinical trial? 
a. 1-3 
b. 4-7 
c. 8 or more 
d. Other___ 
9 Do you run into any of the following issues during the pre-award stage of the clinical trial 
process?  
a. Interpersonal communication issues 
b. Lack of response 
c. Lack of resources 
d. All of the above 
e. Other_____ 
10 Were you able to overcome those issues? 
a. Yes 
b. No 
c. If yes, how did you overcome those issues? 
11 What clinical trial pre award management organization techniques would you pass on to 
an analyst working on clinical trials for the first time? Please explain. 
12 What would you tell an analyst working on clinical trials for the first time NOT to do 
when managing the pre award side of a clinical trial. Please explain. 
 
Do you specialize in the Post-Award portion of clinical trial management? 
a. Yes 








If you answered "Yes" to the above question, please answer questions 14-19. If you answered 
"No," then proceed to the end of the survey. 
 
13 Please select the post-award responsibilities that align with your role in terms of clinical 
trial management from the list below. Check all that apply. 
a. Billing and invoicing 
b. Tracking patient visits, clinical trial milestones 
c. Managing expenditures ensuring they’re allowable, allocable, and reasonable 
d. Report reconciliations 
e. Effort allocations and certification 
f. Award Close Out 
g. All of the above 
h. Other___ 






15 Please choose from the following tracking systems that  you use when managing clinical 
trials.   
a. Personally developed word document, excel sheet, etc. 
b. Institutional provided word document, excel sheet, etc. 
c. Institutional web based tracking system 
d. Other___ 
16 When you have concerns or questions regarding post award management of a clinical 
trial, what resources are available to assist you? 
a. Mentor in the current role 
b. A designated manager or administrator who specializes in clinical trials and or 
sponsored research? 
c. Institutional website with web based policy guides?  
d. All of the above 
e. Other___ 
17 What clinical trial post award management organization techniques would you pass on to 
an analyst working on clinical trials for the first time? Please explain. 
18 What would you tell an analyst working on clinical trials for the first time NOT to do 
when managing the post award side of a clinical trial. Please explain. 
 
 
Thank you for your participation! Your responses will help Katherine's research to improving the 
















Appendix A: Department of Medicine Initial Clinical Trial Management Guide 
 
Created By: Katherine Best 
Grants and Contracts Analyst Allergy and Clinical Immunology Division 
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This guide is intended to be used as a resource in the initial stages of clinical trials.  Johns 
Hopkins University analysts new to managing clinical trials currently do not have access to a 
clinical trial guide assisting them in the initial stages of managing clinical trials. While there is 
information available, there is currently no guide that pieces together the initial steps and stages 
of what departments are involved in clinical trials, the forms required by those departments, and 
the submission requirements by the university. This guide closes that structural gap and provides 
researchers, analysts, and any personnel working on clinical trials with access to clinical trial 



























• The World Health Organization (WHO) defines a clinical trial as “any research study that 
prospectively assigns human participants or groups of humans to one or more health-
related interventions to evaluate the effects on health outcomes. Interventions include but 
are not restricted to drugs, cells and other biological products, surgical procedures, 
radiological procedures, devices, behavioural treatments, process-of-care changes, 
preventive care, etc.” 
• The U.S. National Institutes of Health (NIH) defines a clinical trial as: " A research study  
in which one or more human subjects are prospectively assigned to one or more 
interventions (which may include placebo or other control) to evaluate the effects of 
those interventions on health-related biomedical or behavioral outcomes.”  
Clinical Trial Agreement 
• A Clinical Trial Agreement (CTA) is a legally binding agreement that manages the 
relationship between the sponsor that may be providing the study drug or device, the 
financial support and /or proprietary information and the institution that may be providing 








• A document with important information about a medical procedure or treatment, a 
clinical trial, or genetic testing. It also includes information on possible risks and benefits. 
If a person chooses to take part in the treatment, procedure, trial, or testing, he or she 
signs the form to give official consent. 
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/consent-form 
Data Use Agreements (DUA) 
• Where faculty are receiving or sharing human subject data as part of a research 
collaboration, they will need to ensure that an appropriate Data Use Agreement or other 
form of research collaboration or confidentiality agreement is in place.  
https://homewoodirb.jhu.edu/documents/data-use-agreements-dua/  
Institutional Review Board (IRB) 
• An administrative body established to protect the rights and welfare of human research 
subjects recruited to participate in research activities conducted under the auspices of the 
organization with which it is affiliated. The Institutional Review Board has the authority 
to approve, require modifications in, or disapprove all research activities that fall within 
its jurisdiction. 
https://grants.nih.gov/grants/glossary.htm#P 
Investigator’s Brochure (IB) 
• The Investigator’s Brochure (IB) is a comprehensive compilation of clinical and 
nonclinical data on the investigational product (drug, supplement, device or other 
product) maintained by a drug developer or investigator that contains the body of 






information about the investigational product obtained before and during a drug trial. The 
IB is a document of critical importance throughout the drug development process and is 
updated with new information as it becomes available. 
https://www.research.colostate.edu/ricro/qa/investigators-brochure/ 
Material Transfer Agreement (MTA) 
• A legal document defining the conditions under which research or other materials can be 
transferred and used among research laboratories. 
https://grants.nih.gov/grants/glossary.htm#P 
My Research and Agreement/Application Place (MyRAP) 
• MyRAP is a new Johns Hopkins University-wide online system developed to provide PIs 
and their administrative Partners real-time access to the status of their research 
agreements and contracts as they are being reviewed, negotiated and processed by the 
Offices of Research Administration (ORA). 
https://res.jhu.edu/system_myrap.html 
A non-disclosure agreement (NDA), also known as a confidential disclosure agreement (CDA) 
or secrecy agreement  
• Provides parameters and protections to the parties exchanging confidential or proprietary 
(non-public) information.  Any Johns Hopkins University faculty, student, or employee 




• The pre-award phase represents the beginning of the grant lifecycle, which includes 
announcing opportunities, submitting applications, and reviewing applications. 
https://www.grants.gov/learn-grants/grants-101/pre-award-phase.html 
Principal Investigator 
• The person(s) in charge of a clinical trial or a scientific research grant. The principal 
investigator prepares and carries out the clinical trial protocol (plan for the study) or 
research paid for by the grant. The principal investigator also analyzes the data and 
reports the results of the trial or grant research. Also called PI. 
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/principal-investigator 
Prospective Reimbursement Analysis (PRA)  
• Is a systematic review of a clinical research study protocol, draft contract and sponsor 
budget, proposed Informed Consent Form (ICF) cost language and other documents, 
when applicable, including the Notice of Grant Award (NOGA), Investigator’s Brochure 
(IB) and information regarding the FDA status of the investigational item(s).  PRAs are 
necessary for all research studies that have the potential to generate a hospital facility 
charge and/or professional charge.   
https://ictr.johnshopkins.edu/wp-content/uploads/2019-CRSS-Final.pdf 
Protocol 
• Formal description and design for a specific research project. A protocol involving 
human subject research must be reviewed and approved by an Institutional Review Board 
(IRB) if the research is not exempt, and by an IRB or other designated institutional 
process for exempt research. 
https://grants.nih.gov/grants/glossary.htm#P 






Scope of Work 
• The aims, objectives, and purposes of a grant; as well as the methodology, approach, 
analyses or other activities; and the tools, technologies, and timeframes needed to meet 
the grant's objectives. This includes the research or training plan included with the 
original grant application, along with any approved modifications. 
https://grants.nih.gov/grants/glossary.htm#S 
Sponsor 
• One or more designated individual(s) responsible for providing the fellow with research 








































Offices to Know 





Is an office created to provide 
centralized support and ongoing 
instruction to clinical research teams 
regarding Prospective Reimbursement 
Analysis (PRA), budget development, 




Clinical Research Support 
Services (CRSS) 
750 E Pratt St 14th fl 
Phone 410-361-8362 




Budget Contact: Lisa Wallace 
Associate Director ORASOM 





PRA Development Contact: Cindy 
Elliott 





Clinical Trial Status Contact:  
Jared Nipper 
Sponsored Projects Associate 
















& Support Team 
(RAST) 
 
The Department of Medicine 
Research Administration & Support 
Team (RAST) is a resource for 
sponsored research that maintains 
compliance and integrity in award 
management, ensures excellent 
customer service and provides 
sponsored research training. 
  
Department of Medicine (DOM) 
Research Administration & 
Support Team (RAST) 
1830 E Monument St Ste 9043 
 
Contact:  Elaine Thomas 
Grants & Contracts Manager 
JHU School of Medicine 
Department of Medicine 
Research Administration Services 







The Office of Research 
Administration (ORA) reviews and 
negotiates all grant and contract 
proposals and awards for the School 
of Medicine, including commercially-
sponsored clinical research 
agreements. This includes all federal 
contracts, foundation awards, all grant 
awards, all contracts for clinical, pre-
clinical and non-clinical research, 
consulting agreements, unfunded 
collaboration agreements, data use 
agreements, materials transfer 
agreements, 
confidentiality/nondisclosure 
agreements, and all outgoing 
subawards/subcontracts. 
SOM Office of Research 
Administration 
Edward D. Miller Research 
Building, Suite 117 







Signing Official /Reviewer 
Contact: Sharel Brown 
Associate Director, Grants / 
Authorized Official 
Office of Research Administration 













The Clinical Research Contracting 
group reviews and negotiates all 
commercial Clinical Research 
agreements. 
 
SOM Office of Research 
Administration 
Edward D. Miller Research 
Building, Suite 117 













Johns Hopkins Medicine 
Clinical Research Administration 
750 E. Pratt Street 
14th Floor 
Baltimore, MD  21202 
Phone 410-361-8362 




Initial Contact:  Patricia Previll 
Sponsored Projects Specialist 




Signing Official Contact:  Carlos 
Braxton 
Associate Director ORA SOM 





Contract Reviewer Contact: 
Jennifer M. Williams, M.S., J.D. 
Contract Associate 
Office of Research Administration 
Phone: 410-361-8369   







JHTV aims to maximize the impact of 
Johns Hopkins University's research 
excellence by facilitating the 
translation and commercialization of 
discoveries into accessible 
technologies, products and services 




Johns Hopkins Technology 
Ventures 
1812 Ashland Avenue, Suite 110 
Baltimore, MD 21205 
 
Contact: Jackie N. Anderson 
Technology Transfer Specialist 





Clinical research within The Johns 
Hopkins Health-System is supported 
The Johns Hopkins Hospital – 
Osler Investigational Drug Service 







(IDS) at The 
Johns Hopkins 
Hospital 
by Investigational Drug Service (IDS) 
staff at The Johns Hopkins Hospital, 
Johns Hopkins Bayview Medical 
Center, Sibley Memorial Hospital, 
Suburban Hospital, All Children’s 
Hospital, and at Howard County 
General Hospital (HCGH). These 
locations all provide comprehensive 
pharmacy services to support clinical 
trials, such as: 
• Pharmacist review of all 
medication orders and 
monitoring parameters, if 
applicable 
• Drug preparation and 
dispensing 
• Drug information to patients 
and healthcare team 
• Drug management, 
accountability and regulatory 
support for clinical trials 
(Note: Suburban and HCGH 
do not use electronic inventory 
management at this time) 
• Support development of 
clinical trials, including:  
o Protocol Review 
o Development of 
pharmacy budget and 
invoice for services 
o Review of 
Investigational Drug 
Data Sheet (IDDS) 
o Review of order sets 
o Participate in quality 
assurance activities for 
clinical protocols 
o Staff education 
 
Location: Osler 100 
Hours: Monday through Friday, 
7:30 AM to 5:30 PM 







Contact: Jim Monolakis, PharmD, 







Sponsored Projects will set up and 
maintain each award’s master data 
elements and monitor awards for 
compliance with applicable 
regulations and institutional 
Johns Hopkins at Keswick 
3910 Keswick Road, 5th Floor 
Baltimore, MD 21211 
Phone: 443-997-8151 
Fax: 443 -997-8419 























policies.  It will complete financial 
reporting to external sponsors and 
close out awards within the SAP 
system according to sponsor 
requirements.  It will serve as a 
resource to departmental 
administrators and researchers in all 
aspects of post-award financial 
administration. 
 




Contact: Erika Tringali 
Sponsored Projects Accountant 
Supervisor 
Department of Medicine 










Initial Stages of Clinical Trial Flow Chart 
 
Organization of clinical trials is essential in the early stages of a prospective project. In the flow 
chart found below, the beginning of a clinical trial starts with PI approaching their personnel 
with the information that a prospective clinical trial is in the works. From there, the analyst then 
begins the pre-award clinical trial process, and starts by collecting the necessary information 
needed from the PI and their study team. The information needed includes, but is not limited to;  
1. Project title 
2.  Protocol IRB Number 
3. Scope of work 
4. Consent Form 
5.  Investigator’s Brochure (IB) 
6. Agreement in word format 
7. Sponsor contact for contract information 
8. Email from the sponsor stating they will support this project 
9. Email including all documents sent over by the sponsor for review and negotiation 
(inclusive of MTA, DUA, CDA, DUA, etc., and other contractual documents to be 
reviewed and negotiated documents) 
10. CRSS budget checklist completed 
11. CRSS supplemental information sheet completed 
12. COEUS questionnaires/PI Certification completed  
The analyst must then simultaneously start the COEUS PD, clinical trial checklist, reach out to 





Clinical Trial initiated by PI
Analyst Begins Pre-Award 
Clinical Trial Process
Initial clinical trial 
information 
collected  
Analyst creates COEUS PD 
Analyst begins clinical trial 
check list
Analyst reseches out to CRSS for 
budget initation
Analyst reaches out to Pharmacy 
for pharmacy budget based on 
protocol, consent forms, and 
sponsor brochure






Email Examples to PI, CRSS, Pharmacy 
Analysts reaching out to their PI’s should ensure their email includes all of the required 
documents required by the DOM ORA approvers who review the submitted COEUS PD, CRSS, 
and the pharmacy. All documents should then be loaded into the COEUS PD system, and 
emailed to the appropriate contact information. Training and the COEUS PD instructions can be 
found via the links below. 
• COEUS Training: https://research.jhu.edu/oris/first-steps/  


















































Clinical Trial Checklist 
 
Once all emails to the PI, CRSS, and the Pharmacy are sent out, the analyst should ensure to 
reference and keep track of all incoming information in file folder on a secure place within their 
institutional server. To keep track of what has or has not come in, the analyst should reference 
the clinical trial pre-award checklist, shown below, to ensure they have all the documents needed 













Important Forms to be Completed by PI 
 
CRSS Budget Checklist 
The following information is required in order to complete a draft budget. Please gather all 
information before returning the checklist.  
 




Study Location:   
Department:  
1. Names, Roles and Salaries of study team or other personnel who require support. 
2. Pharmacy Budget (please attach to the email the original budget document received from 
pharmacy) 
3. Number of patients to be budgeted 
4. Is there a departmental Surcharge ( how much) 
5. SAC (Specimen Accessioning Core) Budget –Oncology only (please attach to the email 
the original SAC budget) 
6. Please provide any ancillary department budget if required (ECHO lab, OR, Surgery, 
Anesthesia) 
7. Using ICTR/CRU   Yes    No 
8. List of Services provided by ICTR/CRU for this study (please list all services ICTR/CRU 
will provide on study)  
9. ICTR budget (Main Campus)(Bayview) (please list all services ICTR will provide on 
study) 
10. Where will patients be seen for study visits?  Is this regulated or unregulated space? 
11. Using Clinical Engineering   Yes  No 
12. List of devices supplied by sponsor requiring Clinical Engineering certification ( i.e. 
Holter monitors ) 
13. Will patient be compensated for their study visits?  If so please detail exactly how they 
will be compensated and the dollar amount.  Petty cash, Check request,  JHU preloaded 
card Bank of America,  Outside vendor ( Greenphire, CLIN card or other) please specify.  
Do you need assistance setting up the process?  Yes   No 
14. Sponsor Draft Budget template and CTA submitted to CRSS   Yes  No 
15. Will any blood work be sent to a central lab?(please list all bloodwork going to central 
lab) 
16. Will there be split samples for any bloodwork? 
17. Is this study a JHCRN study?  Yes  No 
18. If yes, which JHCRN sites will participate: List all applicable 
19. Is this a CAPRES Study?  Yes  No 
20. Has the study been submitted to COUES for contract Review? Date? PD number? 
21. Name and contact information of sponsor contact for negotiations. 






JOHNS HOPKINS UNIVERSITY – SCHOOL OF MEDICINE – OFFICE OF RESEARCH ADMINISTRATION 
SUPPLEMENTAL INFORMATION SHEET 
(FOR COMMERCIAL AGREEMENTS) 
 
PI: ___________________________ SPONSOR:   ____________________________________ 
  
PROJECT TITLE:    
_________________________________________________________________________________ 
 
I. Type of Study: (CHECK ONLY ONE 
  Clinical Research  Defined as:  All commercial clinical research that involves patients or PHI,  or clinical 
testing or procedures, or drug/device diagnostic testing in humans or any planning/lab/clinical service in support 
of such clinical research. Please send directly to Clinical Research Contracting, 1629 Thames Street, Suite 200, Baltimore, MD 
21231 or email: ORACONTRACTSFP@jhmi.edu 
  Other Research (anything other than clinical research as defined above)  
  Includes (Check ALL that apply) 
  Materials provided by sponsor or other (with a commitment to conduct specific research) 
  Funding by sponsor or other Equipment provided by sponsor or other  Other 
collaborations  
  Other  (e.g., services, lab analysis, etc.) Please specify  ________________________________ 
II. Documents (REQUIRED) for Review of Agreements   
 
 A. Contract documents (items a-c) 
   a.  Copy of proposed contract paper  and/or    electronic (preferred) 
   b.  Statement of work (protocol abstract, description) 
   c.  Other relevant documents (e.g. invention disclosure, investigator agreement, etc)  
B. Sponsor contact information for contract negotiation a copy of correspondence or e-mail is acceptable).  
    
  Name       Phone         
 Fax       e-mail    
  
 
III. Protocol/Study Information 
 
 A. Protocol/Study developed by:    Sponsor    JH Investigator  Other Name: ________ 
 B. If human subjects are involved: 
  Investigational drug/device   Y   N  
  If yes, IND/IDE held by:   Sponsor  JH Investigator     Other (Name: 
_____________________________ 
   (provide IND/IDE number and/or a copy of the FDA letter) ________________________________ 
 
C. Will any other sponsored support or JHU, third party intellectual property (“IP”) or proprietary material be 
used in this research? 
 Y  N 
  If yes, provide information regarding type of support (drug, device, dollars, IP), and sponsor 
award number and Internal Order (IO) number (if active); or Sponsor name and project title (if pending) 
and third party agreements.  
 
 
IV. Will any portion of the work be done at another site, including JH affiliates (ie, Anne Arundel Medical 
Center, GBMC)?  
 
Y  N    (If YES, complete information in section VII for each site) 
 
V. Student participation.  Provide the names and assigned departments of all students 
(undergraduate/graduate/fellows/residents), and the name of the appropriate mentor, participating in the study on 
a separate sheet, so ORA can generate assignment documents.  
 






VI. Priority (select A or B below) (also select C where applicable) 
 
  A.  Urgent -- The following are eligible for urgent review: compassionate use, limited site 
selection, capped accrual, or other emergent need.  To be eligible for urgent review, an explanation of 
the reason for urgent review MUST be provided below.  Without an explanation the agreement will be 
treated as Routine. 
 
   (EXPLAIN): 
___________________________________________________________________________________
___  
  Note:  Protocol must be submitted to the IRB before or simultaneously with ORA receipt of contract to 
be considered Priority A and eligible for urgent review.  Please provide a copy of the submission (minimally the first 
page of the form). (ORA initial review within five business days)   
 
  B.  Routine -- All other corporate agreements, investigator initiated clinical trials, basic research 
agreements.  (ORA initial review within ten business days) 
 
  C. Master or Model Agreements - - Studies that are being done under a Master Agreement, 
Model Agreement, or where the company has used a JHU template. 
 
  NOTE:  Agreements that are under a Master Agreement or use the JHU model template or 
where JHU has an agreed Model with a sponsor may take less time to review and negotiate. 
 
VII. Other site information (copy and complete for EACH site)  
 
Site name:  
Contracting Official Name:  
Contracting Official Title:  
Address (both USPS and 
Express): 
 








A.  Will vertebrate animals be used at site?  Yes  No   
 If yes, does site have its own IACUC?  Yes  No  
 
B.  Are human subjects involved at site?  Yes  No   
 If yes, is IRB covered by JHU?  Yes  No  
 C.  Will JHU send PHI TO Subrecipient?   Yes  No  
 D.  Will Subrecipient send PHI to JHU?  Yes  No  
 
 E.  Does Subrecipient have its own Conflict of  















Principal Investigator:  
Proposal Number:  








Signature:  ____________________________________________________________ 
 
Yes No Have lobbying activities been conducted on behalf of this proposal? 
 
Yes No Can you certify that the information submitted within this application is true, 
complete and accurate to the best of your knowledge?  Please be aware that any 
false, fictitious, or fraudulent statements or claims may subject you, as the 
PI/Co-PI/Co-Investigator to criminal, civil or administrative penalties. 
 
Yes No Do you (or your spouse, domestic partner, or dependent children) have a 
financial interest or fiduciary relationship that 1) could be affected by the 
research or 2) is an entity that could be affected by the research?  This applies 
to current interests/relationships and those within the past 12 months.  A 
financial interest or fiduciary relationship includes, for example, receipt or 
contractual entitlement to royalty, equity, or consulting remuneration, 
employment, and service as an office or Board of Directors member.  If you 
answer yes to this question, you must disclose your financial interest or 
fiduciary relationship in the JHU online disclose system, eDisclose 
(http://edsiclose.jhu.edu)  
 
Yes No Are you currently debarred, suspended, proposed for debarment, declared 
ineligible or voluntarily excluded from current transactions by a federal 
department or agency? 
 
Yes No Do you agree to accept responsibility for the scientific conduct of the project 
and to provide the required progress reports? 
 
Yes No Have you completed the Conflict of Interest training? 
 
Yes No Have you completed the Responsible Conduct of Research training? 
 






JHU COEUS CCQ Conditional Compliance Questions 
1. Q1009_Does this project involve use of bio-hazardous materials, radioactive materials, 
hazardous chemicals, or recombinant DNA?    
• Q1047_If Yes: Does this project involve the use of biohazardous 
materials?  If yes, be sure to complete the Special Review Tab.    
• Q1010_Does this project involve use of radioactive materials? If yes, be 
sure to complete the Special Review Tab.    
• Q1011_Does this project involve use of hazardous and highly-toxic chemicals 
(e.g., carcinogens, mutagens, chemicals NIOSH IDLH level)? If yes, be sure 
to complete the Special Review Tab.  
 
• Q1012_Does this project involve use of recombinant DNA?  If yes, be sure to 
complete the Special Review Tab.    
2. Q1013_Will the project necessitate alterations or renovations?    
• Q1031_If Yes: Please provide an explanation of the required alterations.    
• Q1044_Have the alterations/renovations been approved by the Dean's Office?    
3. Q1014_Will additional space be needed in any project location?    
• Q1032_If Yes: Please add an explanation of the additional space request.   
• Q1042_Has space request been approved by the Dean's Office?   
4. Q1016_Do you anticipate that program income will be generated under this project?   
• Q1034_If Yes: Please provide an explanation for the anticipated program income.  
 
5. Q1026_Is cost sharing or matching required by the sponsor?   




• Q1045_Please provide cost centers and/or internal orders that will be used for 
cost sharing.  
 
6. Q1018_In this project, will you be utilizing information provided under a confidentiality 
agreement with a third party?    
• Q1035_If Yes: Please provide the name of the third party(s) with whom you 
have the confidentialy agreement.    
7. Q1083_Science Codes pertaining to University's Strategic Initiatives contained is this 
research. Select all Codes that apply; select 'None', if appropriate 
• 21st Century Cities: Project addresses the needs or extends the promise of cities 
• Baltimore: Project invests in Baltimore and its citizens 
• Big Data: Project involves data-intense research 
• Global Health: Project involves global health inequities research 
• Hopkins in Health: Project involves individualized health research 






• Kavli Initiative: Project connected to Kavli Neuroscience Discovery Initiative 
• None: No University Stategic  Initiative Science Codes apply 
• Science of Learning: Project connected to learning throughout the lifespan 
• Space Studies: Project involves civil space? related activities. 
8. Q1084_Science Codes pertaining to Medical or Health characteristics of this research. 
Select all Codes that apply; select 'None', if appropriate. 
• AIDS/HIV: Project involves AIDS/HIV research 
• Cancer: Project involves cancer research 
• HIPAA: Participants must sign a HIPAA form (Health Insurance Portability & 
Accountability Act 
• None: No Medical or Health Related Science Codes applyVaccine: Project 
involves development of a vaccine or testing vaccine effectiveness 
• Womens Health: Project involves research into womens health 
9. Q1085_Science Codes pertaining to Funding of this proposal. Select all Codes that 
apply; select 'None', if appropriate. 
• Administrative Supplement: Sponsor will approve proposal based on an 
administrative, not competitive, review 
• Competitive Supplement: Sponsor will approve proposal based on competitive or 
peer review 
• Confidential Agreement: Project involves a non-disclosure agreement or 
Confidentiality Agreement that may be either in negotiations or fully executed. 
Proposal Type Negotiations Only. 
• Intergovernmental Personnel: Proposal will allow an individual to remain 
on JHU payroll while providing service to a governmental entity. 
Proposal Type Negotiations Only. 
• Master Agreement: Proposal is the initial Negotiated agreement with no dollars 
specified (Proposal Type Negotiations Only), after which Task Orders will be 
issued (Proposal Type Task Order). 
• None: No Funding Proposal Science Codes apply). 
10. Q1086_Science Codes pertaining to the General Purpose of this proposal. Select all 
Codes that apply; select 'None', if appropriate. 
• Career or Young Investigator: Designed to promote the new research career of 
PI, for example: NIH K awards, NSF Career awards, ONR Young Investigator 
awards, or other sponsors such as Beckman Young Investigator Progam 
• Change of Grantee Institution: Proposal requests the transfer of an award, 
grant, from another institution to JHU. 
• Internal Proposal: Open solicitation through a JHU department of center. 
• International Programs: Proposed research involves work of a foreign 
country, its citizens, its organizations, or its institutions, such as foreign 
subrecipients. 






• No-Cost Extension: Proposal requests modification of an award, grant, but only 
to extend the period of performance. 




























JHU DOM MCQ Mandatory Compliance Questionnaire 
1. Q1005_Does this project involve the use of identifiable human subjects via contact, 
data/records and/or survey, or the use of human tissue, serum, or other fluids? If yes, be 
sure to complete the Special Review Tab.  
 
• Q1006_If Yes: Does this project involve disclosure/receipt of protected 
health information to/from sponsor or third parties?    
• Does this grant proposal contemplate the use of a single IRB (SIRB) to 
review the human subject research proposed? Upload your letter of support 
from the appropriate JHU IRB for the proposed sIRB. 
2. Q1007_Does this project involve use of any of the following: human embryonic stem 
cells (hESCs), somatic cell nuclear transfer (SCNT) involving human cells or other 
human pluripotent stem cells (hPSCs) that are already subject to oversight by the JHU 
Institutional Stem Cell Research Oversight (ISCRO) Committee 
(http://www.hopkinsmedicine.org/Research/iscro/)?    
• Q1054_If Yes: Have you obtained review and approval from the Stem 
Cell Research Oversight Committee (JHU ISCRO)?    
3. Q1100_Is this a multi-site study?   
4. Q1008_Does this project involve use of live vertebrate animals?  If yes, be sure to 
complete the Special Review Tab.    
5. Q1015_Are any administrative costs included in the budget?    
• Q1033_If Yes: Please provide an explanation for the administrative costs 
requested.  
 
6. Q1027_Has the Principal Investigator completed the required effort reporting training?    
7. Q1017_Will the project include subawards or subcontracted effort to other organizations?    
8. Q1104_Does any named JHU investigator (or any immediate family member of a named 
JHU investigator) have an ownership or equity interest in any proposed subrecipient? 
 
9. Q1105_Does any proposed subrecipient employ any immediate family member of a named 
JHU investigator? 
 
10. Q1107_Will there be any foreign subrecipients?   
11. Q1019_In this project, will you be utilizing materials provided under a Material Transfer 
Agreement (MTA) with a sponsor and/or third party?    
• Q1036_If Yes: Please provide the name of the company or institutions with 
whom you have or may have the material transfer agreement.    
12. Q1020_Do you anticipate that this project will involve existing JHU intellectual 
property (yours or another investigator's), such as inventions, copyrights, etc?   
• Q1037_If Yes: Please identify the JHU disclosure number.    
13. Q1038_Has the proposed use been approved by Johns Hopkins Tech Transfer?   






14. Q1066_Will any item or information used or developed during the proposed project a) be 
the product of  defense funding, b) be designed, developed, configured, adapted, or 
modified specifically for a military, space or intelligence application, or c) have 
potential, military, space or intelligence applications?    
15. Q1092_Will the project include or anticipate a Johns Hopkins Clinical Research Network 
(JHCRN) as a sub site or participant in this study?   
16. Q1095_Is this proposal, in any way, a result of Catalyst or Discovery award funding?  
17. Q1098_Do you: 
• - have access to non-public information, or 
18. have you performed or do you expect to perform work for the federal government; 
that may provide you or another member of The Johns Hopkins University with an 
unfair competitive advantage in applying for federal funding or that could appear to 
bias its judgement?Q1108_Does this proposal relate to COVID-19 work?    
19. Q1109_Does this proposal involve funds coming from the Coronavirus Aid, Relief, and 
Economic Security (CARES) Act?    






















JHU DOM MIQ Mandatory International Questionnaire 
21. Q1055_Will your project require the involvement of any foreign country, its citizens or 
organizations? Please use the link to the right if you are uncertain how to interpret this 
question. 
• Q1056_If Yes: Will any of the proposed project activity take place within a 
foreign country?  
 
• Q1057_If Yes: Please select a foreign country (you will have the 
opportunity to select additional foreign countries). 
• Q1058_If Yes: Please select the type of activity that you expect to occur in this 
country. 
1. A subcontract with a foreign university or entity 
2. Hiring independent contractors or employees 
3. Opening a foreign bank account 
4. Leasing space 
5. An American or foreign national receiving project-related items 
including, but not limited to, equipment, information, and/or data 
6. Participating personnel traveling to, or sponsoring an activity in, a 
foreign country (e.g., a conference or meeting) 
7. University employees or students working in a foreign country for more than 
ninety (90) days 
8. Other – Answer Yes to Question #3 below, and a space will be provided for 
a description or your planned activity. 
2. Q1070_Do you need additional space to describe the type of activity you expect will take 
place in this country? 
 
 
• Q1071_If Yes: Please describe the Other activity that is expected to take place in 
this country: 
3. Q1060_Do you need to select another country?    
• If yes, please select a foreign country (you will have the opportunity to 
select additional foreign countries) 
• Please select the type of activity that you expect to occur in this country. 
1. A subcontract with a foreign university or entity 
2. Hiring independent contractors or employees 
3. Opening a foreign bank account 
4. Leasing space 
5. An American or foreign national receiving project-related items 
including, but not limited to, equipment, information, and/or date 
6. Participating personnel traveling to, or sponsoring an activity in, a 
foreign country (e.g., a conference or meeting) 






7. University employees or students working in a foreign country for more than 
ninety (90) days 
8. Other – Answer Yes to Question #3 below, and a space will be provided for 
a description of your planned activity 
• Do you need additional space to describe the type of activity you expect 
will take place in this country? 
• Do you need to select another country? 
• If yes, repeat steps above. 
4. Q1061_ During your project, will you provide foreign persons with access to devices, 
materials, source code or technical know-how while they are in the United States?    
• Q1063_If Yes: Please provide as much of the following information as you can 
about any foreign person, to whom you expect to provide access to project-
related devices, materials, source code or technical know-how: 
• - full legal name, 
• - country of citizenship, 
• - concurrent enrollment in, or employment at, foreign universities or companies, 
• - role in the proposed project (e.g., JHU faculty, staff, student lab assistant, 
collaborator, vendor, or independent contractor), 
• - the parts of the project in which they will be involved and what they are 
expected to contribute to them 
5. Q1061_ During your project, will you provide foreign persons with access to devices, 
materials, source code or technical know-how while they are in the United States?    
6. Q1090_In addition to the foreign persons whom you described above, do you 
reasonably expect that other, presently unknown foreign persons will also be provided 
with access to devices, materials, source code or technical know-how, while they are 
in the United States?    
7. Will there be any restrictions placed upon:  a) the publication of project results, or b) 
the inclusion of foreign persons in some or all project activities?    
• Q1065_If Yes: In the text box below, please describe the kind of publication 
and/or access restrictions that you believe will apply to the conduct of your 
project.  
 
8. Q1067_ Are any foreign countries associated with your project subject to sanctions 
implemented by the Treasury Department’s Office of Foreign Assets Control (OFAC)? 
This would include any country that you have      disclosed in other Research Compliance 
Questions, either because project-related activities are expected to take place within that 
country’s boundaries, or because one of its citizens will contribute to the project in any 
way.  If you do not know if a particular country is subject to OFAC sanctions, then use the 
link to an OFAC Web page that is provided in the Regulations section of the guidance 
information provided for this question. The link should lead to a list of currently 




































Initiation of Clinical Trial 
 
Once the analyst has collected all the required information from the PI, the analyst then reviews 
the clinical trial checklist to ensure they have all required documents. Once the checklist has 
been completed, the analyst uploads and submits all documents through the COEUS system. The 


















After all negotiations between the JHU ORA offices and clinical trial sponsor have been 
finalized, and the official agreement signed, the SPSS Office provides the analyst with an email 
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